Please login to the form below

Not currently logged in
Email:
Password:

GlycoVaxyn appoints Gerd Zettlmeissl as chairman

He will join the Swiss vaccines company in June

Swiss vaccines company GlycoVaxyn has appointed Gerd Zettlmeissl as chairman of the board of directors with effect from June, when he will take over from Michel Greco.

"Having worked very closely with Gerd at Intercell for a number of years, I am convinced that he will bring a wealth of development experience and entrepreneurial spirit to this very promising company," Greco said.

"Having chaired the board for more than seven years, I will work very closely with Gerd to ensure a smooth transition," he added.

Zettlmeissl has more than 20 years of experience in developing and commercialising vaccines and spent almost 10 years in executive positions at Intercell.

He served first as its chief operating officer from 2001 to 2005 and then as CEO from 2005 until May  2011.

Prior to joining Intercell, Zettlmeissl served as international head of industrial and quality operations at Chiron Vaccines, and managing director of Chiron Behring GmbH & Co.

He currently serves on the boards of several biotechnology companies including Aeras, an organisation dedicated to the development of tuberculosis vaccines.

6th March 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics